• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»EULAR 2026

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

By Pallavi Madhiraju on June 3, 2026   Pharma & Biotech  

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!

Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens

By Pallavi Madhiraju on June 3, 2026   Pharma & Biotech  

Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens

Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.

Recent Posts

  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
  • Why Multi Radiance Medical’s MR5 ACTIV PRO clearance matters for tendon pain treatment
  • Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
  • Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset
  • Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight
  • Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes